Advancing Therapeutics,

Improving Lives

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.

Our portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Gilead is committed to address the unmet medical need in China through bringing forward our innovative products to the patients here. The company has been present in China since 2007, starting with manufacturing and growing over time to include the establishment of commercial operations based in Shanghai in 2016. In September 2017, the China Food and Drug Administration (CFDA) approved Gilead’s Sovaldi® (sofosbuvir 400mg), for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen. Sovaldi is the first Gilead HCV medicine to be approved in China. Along with LDV/SOF, Gilead is also studying its HCV single-tablet regimen sofosbuvir/velpatasvir in clinical trials at sites across China.

Strength Through Partnership

Collaborations of all kinds – with partners in science, academia, business and local communities – are central to our work.  Partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible. 

Growing Worldwide Reach

Gilead was founded in 1987 in Foster City, California. Since then, we have grown to become one of the world’s largest biopharmaceutical companies, with 9,700 employees across six continents.

At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.